Skip to main content
Year archive

Enlivex Therapeutics Ltd. — 2022 filings

All 62 regulatory filings released by Enlivex Therapeutics Ltd. (ENLV) in 2022, sourced directly from the official regulator.

62 Filings
2022 Period
2022 filings (62)
Filing Released Lang
An ATM Agreement pursuant to which the Company may elect to sell ordinary shares of the Company
Regulatory Filings
2022-12-31 English
An ATM Agreement pursuant to which the Company may elect to sell ordinary shares of the Company
Report Publication Announcement
2022-12-31 English
PROSPECTUS SUPPLEMENT - pursuant to an at-the-market agreement
Capital/Financing Update
2022-12-31 English
PROSPECTUS SUPPLEMENT - pursuant to an at-the-market agreement
Report Publication Announcement
2022-12-31 English
A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial
Legal Proceedings Report
2022-12-07 English
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Regulatory Filings
2022-12-06 English
Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update
Earnings Release Q3 2022
2022-12-05 English
Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update
Report Publication Announcement
2022-12-05 English
FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2022
Interim / Quarterly Report 9M 2022
2022-12-03 English
FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2022
Report Publication Announcement FY 2022
2022-12-03 English
First Patients Dosed in Phase I/II Trial of Enlivexs Off-the-Shelf Cell Therapy Candidate, AllocetraTM
Regulatory Filings
2022-12-02 English
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
Regulatory Filings
2022-12-01 English
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
Regulatory Filings
2022-11-28 English
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
Report Publication Announcement
2022-11-28 English
Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
Regulatory Filings
2022-11-15 English
Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
Report Publication Announcement
2022-11-15 English
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on November 17, 2022
AGM Information
2022-10-06 English
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on November 17, 2022
AGM Information
2022-10-06 English
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on November 17, 2022
AGM Information
2022-10-06 English
Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022
Regulatory Filings
2022-09-12 English
Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022
Report Publication Announcement
2022-09-12 English
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy
Regulatory Filings
2022-09-06 English
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy
Report Publication Announcement
2022-09-06 English
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells
Regulatory Filings
2022-08-29 English
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells
Report Publication Announcement
2022-08-29 English
Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial
Regulatory Filings
2022-08-24 English
Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial
Report Publication Announcement
2022-08-24 English
Financial and operating results for the three and six month periods ended June 30, 2022
Interim / Quarterly Report H1 2022
2022-08-22 English
Financial and operating results for the three and six month periods ended June 30, 2022
Report Publication Announcement
2022-08-22 English
Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced S
Regulatory Filings
2022-08-17 English
Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced S
Report Publication Announcement
2022-08-17 English
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™
Regulatory Filings
2022-08-03 English
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™
Report Publication Announcement
2022-08-03 English
Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy i
Regulatory Filings
2022-07-06 English
Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy i
Report Publication Announcement
2022-07-06 English
Enlivex Receives Israeli Ministry of Health Authorization for the Initiation of a Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from S
Regulatory Filings
2022-06-06 English
Enlivex Receives Israeli Ministry of Health Authorization for the Initiation of a Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from S
Report Publication Announcement
2022-06-06 English
New Preclinical Data in Ovarian Cancer Showing a Substantial Survival Benefit when Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology (ASCO) Annual Mee
Regulatory Filings
2022-05-31 English
New Preclinical Data in Ovarian Cancer Showing a Substantial Survival Benefit when Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology (ASCO) Annual Mee
Report Publication Announcement
2022-05-31 English
Financial statements for the three month period ended March 31, 2022
Interim / Quarterly Report Q1 2022
2022-05-28 English
Financial statements for the three month period ended March 31, 2022
Report Publication Announcement
2022-05-28 English
Enlivex Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients
Regulatory Filings
2022-05-25 English
Enlivex Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients
Report Publication Announcement
2022-05-25 English
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
Board/Management Information
2022-05-23 English
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
Report Publication Announcement
2022-05-23 English
Enlivex Presented Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2
Regulatory Filings
2022-05-09 English
Enlivex Presented Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2
Report Publication Announcement
2022-05-09 English
Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra
Regulatory Filings
2022-05-05 English
Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra
Report Publication Announcement
2022-05-05 English
Acceleration Request of effectiveness of the Registration Statement
Regulatory Filings
2022-05-04 English
Acceleration Request of effectiveness of the Registration Statement
Report Publication Announcement
2022-05-04 English
Full Year 2021 Financial Results, Completion of Development of Frozen Formulation Allocetra™ Ahead of Schedule, and Provides Strategic & Business Updates
Regulatory Filings
2022-04-29 English
Full Year 2021 Financial Results, Completion of Development of Frozen Formulation Allocetra™ Ahead of Schedule, and Provides Strategic & Business Updates
Report Publication Announcement
2022-04-29 English
F-3, PROSPECTUS, SUBJECT TO COMPLETION, DATED APRIL 29, 2022
Regulatory Filings
2022-04-29 English
F-3, PROSPECTUS, SUBJECT TO COMPLETION, DATED APRIL 29, 2022
Report Publication Announcement
2022-04-29 English
FORM 20-F 2021
Annual Report FY 2021
2022-04-29 English
FORM 20-F 2021
Report Publication Announcement FY 2021
2022-04-29 English
Announces Issuance of Israeli Patent Covering Allocetra Derived from Pooled Donor Cells
Regulatory Filings
2022-03-08 English
Announces Issuance of Israeli Patent Covering Allocetra Derived from Pooled Donor Cells
Report Publication Announcement
2022-03-08 English
Appointment of Biotech Industry Veteran Einat Galamidi, M.D., as Vice President, Medical
Board/Management Information
2022-02-22 English
Appointment of Biotech Industry Veteran Einat Galamidi, M.D., as Vice President, Medical
Report Publication Announcement
2022-02-22 English
Meitav Dash Trade will cease to operate as a market maker in the company's shares as of March 15, 2022
Regulatory Filings
2022-02-22 Hebrew (modern)